Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Decensi

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Journal of the National Cancer Institute|October 17, 1998
Biologic activity of tamoxifen at low doses in healthy womenA Decensi, B Bonanni, A Guerrieri-Gonzaga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2009
Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational studyA Guerrieri-Gonzaga, E Botteri, M Lazzeroni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)K Fujiwara, B J Monk, C Lhommé, et al.
NPJ Breast Cancer|June 9, 2025
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer preventionG Aurilio, D Serrano, M Lazzeroni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2013
Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort studyA Guerrieri-Gonzaga, M Lazzeroni, E Botteri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breastG Pruneri, M Lazzeroni, V Bagnardi, et al.
Tumori|April 4, 1998
Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrualG De Palo, T Camerini, E Marubini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2013
A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT studyA DeCensi, B Bonanni, P Maisonneuve, et al.
Journal of the National Cancer Institute|November 5, 1999
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancerU Veronesi, G De Palo, E Marubini, et al.
British Journal of Cancer|February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum lineN Colombo, A Gadducci, J Sehouli, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of the National Cancer Institute|October 17, 1998
Biologic activity of tamoxifen at low doses in healthy womenA Decensi, B Bonanni, A Guerrieri-Gonzaga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2009
Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational studyA Guerrieri-Gonzaga, E Botteri, M Lazzeroni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)K Fujiwara, B J Monk, C Lhommé, et al.
NPJ Breast Cancer|June 9, 2025
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer preventionG Aurilio, D Serrano, M Lazzeroni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2013
Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort studyA Guerrieri-Gonzaga, M Lazzeroni, E Botteri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breastG Pruneri, M Lazzeroni, V Bagnardi, et al.
Tumori|April 4, 1998
Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrualG De Palo, T Camerini, E Marubini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2013
A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT studyA DeCensi, B Bonanni, P Maisonneuve, et al.
Journal of the National Cancer Institute|November 5, 1999
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancerU Veronesi, G De Palo, E Marubini, et al.
British Journal of Cancer|February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum lineN Colombo, A Gadducci, J Sehouli, et al.
Pageof 10